An early study focused on targeted analysis of proteins known to be linked to melanoma progression and found “melanoma inhibitory activity” (MIA) and S100B to be significantly enriched in sEVs of melanoma patients compared to healthy controls and disease-free patients, whereas TYRP2 showed no difference [141]. This evidence concerns the gene S100B and melanoma.